广济药业定增不超过6亿，长江产业集团拟现金全额认购增发股份

Group 1 - The core point of the article is that Guangji Pharmaceutical has announced a targeted issuance plan to raise up to 600 million yuan, primarily to support its operations amid ongoing financial losses and a challenging market environment for vitamin B2 [1][2][3] - Guangji Pharmaceutical is a major supplier of vitamin B2 and has reported expected losses ranging from 399 million to 518 million yuan for the year 2025, continuing a trend of increasing losses over the past three years [1][2] - The company plans to use the funds raised from the issuance to repay debts and supplement working capital, aiming to optimize its capital structure and enhance its risk resilience and profitability [2] Group 2 - The vitamin market is expected to grow due to increasing health awareness among consumers and supportive national policies promoting high-quality vitamin production [2] - Guangji Pharmaceutical's major shareholder, Changjiang Industrial Investment Group, will fully subscribe to the new shares, indicating strong support for the company's future development [2] - Market research suggests that the vitamin B2 market may enter a period of moderate growth starting in 2026, with potential price stabilization and improved production efficiency due to technological upgrades [2]